UNCY Unicycive Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why UNCY matters now
Unicycive Therapeutics, Inc. (UNCY) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.21 with -0.95% on the session and $112.0M in market capitalization; recent performance reads 1-month -11.38% and YTD +18.72%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-12.8M, and EPS of $-0.54. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -19.5%.
The latest indexable market news headline is "UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc." from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $22.00; recent insider activity includes Kenkare-Mitra Sara filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
43.44
P/S
0.00
EV/EBITDA
-2.82
DCF Value
$0.18
FCF Yield
-19.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-131.2%
ROA
-62.0%
ROIC
-77.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-12.8M | $-0.54 |
| Q4 2025 | $0.00 | $-14.7M | $-0.32 |
| FY 2025 | $0.00 | $-26.6M | $-1.67 |
| Q3 2025 | $0.00 | $-6.0M | $-0.33 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$22.00
Target (Median)
$22.00
Target Range
$22.00 - $22.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.73
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.